David Morris, MD, FACS, discusses how PSMA PET imaging may impact targeted therapies for prostate cancer in the future.
David Morris, MD, FACS, a urologist at Tennessee Urology Associates, discusses how PSMA PET imaging may impact targeted therapies for prostate cancer in the future.
0:08 | PSMA/PET imaging has really exploded in the last year. It's certainly something we've been aware of clinically for several years from Europe or Australia that's been highly used. And we've kind of viewed it with jealousy from the US market. It has not been available; it's not been covered.
0:23 | And as you would expect, the new technology is immediately blossomed where you can obtain it. It's something that's quickly supplanting conventional imaging which was just not as ideal as we would hope for in terms of sensitivity. So as the PSM a market for access has grown, the coverage has actually been better than we anticipated when it first launched. And I think we all recognize it's better than conventional imaging in terms of finding metastatic lesions and with that and enables us to grow our potential patient base for targeted therapy. So, to tell someone that they have metastatic disease earlier or be able to start them on a targeted therapy earlier, and certainly beneficial versus the wait and watch with conventional imaging until they have metastasis detected.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More